Minocycline

Research summary

In healthy human subjects, the available evidence is limited to a bioequivalence crossover study showing that one minocycline tablet formulation was comparable to an approved reference capsule under fed conditions. This supports pharmacokinetic comparability, not health benefits. No healthy-human trials were identified demonstrating clear benefits for cognition, longevity, inflammation, or other wellness outcomes. Overall, the research consensus for healthy people is that minocycline is not a general-purpose supplement. It remains a prescription antibiotic with important safety considerations, and most claimed anti-inflammatory or neuroprotective effects are based on animal, cell, or patient-population studies rather than studies in healthy volunteers.